Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Emerging Markets Earnings Roundup: Pfizer (Part 4)

This article was originally published in PharmAsia News

Executive Summary

Pfizer considers the structure of its pharma operations in emerging markets as the dust begins to settle from its spin-off of its animal health business and the sale of its nutrition business.

You may also be interested in...



Pfizer Suffers Grim Q3, But Management Points To Future Growth Drivers

Pfizer’s revenues fell 16% in the third quarter, as the pharma giant absorbed exclusivity losses including the loss of Lipitor, but management tried its best to highlight long-term growth drivers during a Nov. 1 conference call.

Pfizer Moo’ved To Split Off Zoetis Business By July 2013

Pfizer begins the process to split off its animal health business with an IPO in an effort to save on taxes and refrain from diluting the current shareholder base.

Follow The CEO? Abbott Chief Chooses Diversified Products, Emerging Markets Over Rx Drugs As Company Splits In Two

Abbott Laboratories CEO Miles White has complained for a long time that U.S. investors don't understand the growth opportunity of emerging markets. Now White finally has a chance to put his money where his mouth is, choosing to lead a diversified medical products company rather than an innovative pharmaceutical company that will carry a different name, following a decision to split Abbott into two companies

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1134940

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel